- Assay Development Principles and Good Research Practices for Rigor and Reproducibility in In Vitro Toxicology (AM03)
Feb. 22, 2019
1-2 p.m. ET
Rare diseases affect an estimated 30 million people in the United States. On Friday, Feb. 22, 2019, 1-2 p.m. ET, NIH will host a Twitter Chat on rare diseases. The chat will feature NIH Director Francis S. Collins, M.D., Ph.D., NCATS Director Christopher P. Austin, M.D., NCATS Office of Rare Diseases Research Director Anne R. Pariser, M.D., and many others. Join the conversation by following #NIHChat.
Feb. 28, 2019
8:30 a.m.-4 p.m. ET
Natcher Conference Center (Building 45), Main Auditorium
Sponsored by NCATS and the NIH Clinical Center, Rare Disease Day at NIH will feature speakers, including NCATS Director Christopher P. Austin, M.D.; NIH Clinical Center CEO James K. Gilman, M.D.; and NCATS Office of Rare Diseases Research Director Anne R. Pariser, M.D.
The event will feature interactive panel discussions on collective research models for rare diseases, patient registries, rare cancer research initiatives, and "no disease left behind, no patient left behind." New this year will be a presentation of the first ever Zebbie award for the NCATS Rare Diseases are Not Rare! Challenge. Other highlights include posters and exhibits by rare disease groups and researchers as well as artwork, videos and NIH Clinical Center tours. Admission is free and open to the public. In association with Global Genes®, participants are encouraged to wear their favorite pair of jeans. Be sure to follow the event on social media using #RDDNIH.
Assay Development Principles and Good Research Practices for Rigor and Reproducibility in In Vitro Toxicology (AM03)
March 10, 2019
8:15 a.m.-Noon ET
Baltimore Convention Center
1 West Pratt Street
Baltimore, Maryland 21201
During the Society of Toxicology 58th Annual Meeting & ToxExpo, NCATS scientists will teach sessions designed to provide participants with “good research practices” for the rigorous development, optimization, implementation and interpretation of robust in vitro toxicological assays for reproducible results using physiologically relevant models. Participants will learn how understanding the nature of cells in vitro and treating cells as reagents can ensure the design of more reproducible assays. Strategies will also be shared for the successful implementation of high-throughput assays that enable the rapid and high-throughput assessment of both toxicity and efficacy using in vitro models with increased physiological relevance.
Along with the Assay Guidance Manual, this course will provide attendees with core principles and practices that will facilitate the design and execution of a broad range of rigorous and reproducible assays, increased throughput, and improved in-depth interpretation of data. It will also be beneficial to researchers from industry, government and academic labs who evaluate the safety of experimental compounds and wish to learn more about the latest in vitro models, methodologies and analysis strategies.
Registration for the Annual Meeting and a ticket for this continuing education course are required to attend this session.
May 8–11, 2019
Sheraton Centre Toronto Hotel
123 Queen Street West
Toronto, Ontario M5H 2M9 Canada
The 2019 RE(ACT) Congress, co-hosted by NCATS, will bring together internationally recognized scientific leaders and experts, young scientists, and patients and patient organizations to present and discuss rare disease research. The 2019 Congress, which will be held in Toronto, is the fifth edition of the event and the first to take place in North America. The Congress’s overarching goal is to promote international scientific cooperation in rare disease research. Registration is required.